See You Today at Onyx for ‘Reinventing Biotech’s Business Model’
The Xconomy team is getting ready to head over this afternoon to Onyx Pharmaceuticals for our big event titled “Reinventing Biotech’s Business Model.” More than 160 people have registered online in advance, and there is still a little room for folks who’d like to register at the door.
For those of you who can’t make it there in person, you can follow some of the highlights on Twitter. The searchable hash tag is #xcbiomodels. Given the great lineup of speakers we have assembled from Kleiner Perkins Caufield & Byers, OrbiMed Advisors, GlaxoSmithKline, Third Rock Ventures, Genentech, Pfizer, Versant Ventures, Delphi Ventures and more, I fully expect many smart quotes to zing around the room, the web, and social networks.
Registration and networking starts at 1 pm, and the program will run from 2 pm to 6 pm, with a half-hour networking break in the middle, and plenty more time for schmoozing at the end. See you there!
1 pm. Registration and networking.
2 pm. Welcoming remarks, Onyx Pharmaceuticals CEO Tony Coles & Xconomy’s Luke Timmerman.
2:10 pm. Opening keynote chat. I’m going to moderate a discussion featuring three biotech CEOs at publicly-traded companies who are under the gun to create more innovative products on tight R&D budgets.
—Tony Coles, CEO, Onyx Pharmaceuticals (NASDAQ: ONXX)
—Mike Morrissey, CEO, Exelixis (NASDAQ: EXEL)
—Robert Blum, CEO, Cytokinetics (NASDAQ: CYTK)
2:40 pm. Experiments with new biotech business models. I’m going to ask these speakers to share their adventures in seeking support for startups. These speakers won’t have to vie for attention on some mega-panel, but they will come up front one by one to tell their stories in 20-minute chunks.
—James Sabry, VP of partnering at Genentech, & Mark Goldsmith, venture partner at Third Rock Ventures. These two will be able to talk about how they worked together to support epigenetics R&D at Cambridge, MA-based Constellation Pharmaceuticals.
—Peter Thompson, a West Coast-based venture partner with OrbiMed Advisors, will be able to talk about why this big, diversified fund is concentrating on early-stage investments like Cambridge, MA-based Arteaus Therapeutics.
—Steve Kaldor, CEO of San Francisco-based Quanticel Pharmaceuticals, on Versant Ventures’ unusual partnership to advance this startup’s R&D program with Celgene (NASDAQ: CELG).
—Clare Ozawa, co-founder and chief business officer of Inception Sciences, andBrian Atwood, managing director of Versant Ventures, on creating an incubator that wants to spin out drug assets for Big Pharma to buy—not whole companies.
4 pm. Networking Break.
4:30 pm. In the late afternoon session, we’ll hear from speakers at Big Pharma companies who are charged with rethinking their relationships with innovators in academia and biotech. Each of these individual chats will go about 20 minutes.
—Jens Eckstein, president of GlaxoSmithKline’s SR One venture arm, on how “strategic” corporate venture groups have sought to fill the void during the decline of traditional VC.
—Diego Miralles, head of the Janssen Labs in San Diego, on the various experiments J&J is running to support innovations that it—or its competitors—may want to someday acquire.
—Richard Lindberg, executive director and head of the Centers for Therapeutic Innovation in California for Pfizer. Lindberg will be able to talk about the giant drugmaker’s partnership with UCSF, and what the company hopes will come from it.
5:30 pm. We will seek to put the afternoon’s stories in perspective, and hear some new ideas, from a trio of top biotech VCs. This closing keynote chat will go for about 30 minutes.
—Risa Stack, partner, Kleiner Perkins Caufield & Byers
—Deepa Pakianathan, general partner, Delphi Ventures
6 pm. Networking reception